Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
7,647,947
-
Share change
-
+34,955
-
Total reported value
-
$52,233,830
-
Put/Call ratio
-
93%
-
Price per share
-
$6.83
-
Number of holders
-
42
-
Value change
-
-$1,016,802
-
Number of buys
-
21
-
Number of sells
-
17
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q4 2018
As of 31 Dec 2018,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
42 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,647,947 shares.
The largest 10 holders included
BVF INC/IL, 683 Capital Management, LLC, Vivo Capital, LLC, Nantahala Capital Management, LLC, MEITAV DASH INVESTMENTS LTD, Ibex Investors LLC, BAKER BROS. ADVISORS LP, FIRST MIDWEST BANK TRUST DIVISION, Knoll Capital Management, LP, and UBS OCONNOR LLC.
This page lists
42
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.